Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromoacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromoacetic Acid SCHEMBL2852922 | 0.93 | — | — | |
| Bromoacetic Acid SCHEMBL11405488 | 0.85 | CA4 (0.47) | TSHRCA4TRPA1FAHD1CASP1 | |
| Bromoacetic Acid SCHEMBL6916707 | 0.85 | CA4 (0.47) | TSHRCA4TRPA1FAHD1CASP1 | |
| Bromoacetic Acid SCHEMBL6914854 | 0.85 | CA4 (0.47) | TSHRCA4TRPA1FAHD1CASP1 | |
| Bromoacetic Acid SCHEMBL6914538 | 0.85 | — | — | |
| Bromoacetic Acid SCHEMBL2476064 | 0.85 | — | — | |
| Bromoacetic Acid SCHEMBL6916750 | 0.85 | CA4 (0.47) | TSHRCA4TRPA1FAHD1CASP1 | |
| Bromoacetic Acid SCHEMBL6917043 | 0.85 | — | — | |
| Bromoacetic Acid SCHEMBL789120 | 0.85 | — | — | |
| Bromoacetic Acid SCHEMBL1000560 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| US-20210115031-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3625227-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110621671-A | Benzofuran and benzothiophene derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018210987-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-6593355-B2 | 2-phenylaminomethyl benzimidazole derivatives | BOEHRINGER INGELEHIM PHARMA KG (DE) | 2003-07-15 | — | — | US | disclosed |
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-02 | — | — | US | disclosed |
| US-6451832-B2 | E.G., 2-(AMINDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(ETHOXY-CARBONYL-METHYLAMINO)-1 -(2,5-DIHYDROPYRROLOCARBONYL)-ETHYL)BENZIMIDAZOLE; ANTICOAGULANTS AND ANTITHROMBOLYTIC AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-09-17 | — | — | US | disclosed |
| US-20010006977-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115031-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER4, PTGER1, PTGER2 | GSK3B 4002/4885TSHR 704/4885CA4 2894/4885 |
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | GSK3B 4246/4885TSHR 4410/4885CA4 3787/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | GSK3B 4002/4885TSHR 704/4885CA4 2894/4885 |
| US-20010006977-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | GSK3B 4246/4885TSHR 4410/4885CA4 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.